• Measure Summary
  • NQMC:006141
  • 2010 Apr

Cancer - fatigue/anemia: percentage of known cancer patients who are newly diagnosed with cancer who had an assessment of the presence or absence of fatigue.

RAND Corporation

  • Measure Summary
  • NQMC:006158
  • 2010 Apr

Cancer - information and care planning: percentage of patients with advanced cancer who died an expected death who were referred for palliative care prior to death (hospital-based or community hospice) or there was documentation why there was no referral.

RAND Corporation

  • Measure Summary
  • NQMC:006161
  • 2010 Apr

Cancer - information and care planning: percentage of patients who underwent chemotherapy and, prior to chemotherapy, were informed about the risks and benefits of treatment, including likely symptoms and side effects, and whether the treatment intent is curative or palliative.

RAND Corporation

  • Measure Summary
  • NQMC:006130
  • 2010 Apr

Cancer - pain: percentage of patients treated for spinal cord compression for whom there was follow-up of neurologic symptoms and signs within 1 week after treatment was completed.

RAND Corporation

  • Measure Summary
  • NQMC:006155
  • 2010 Apr

Cancer - delirium: percentage of hospitalized patients with cancer over the age of 65 or with advanced cancer with delirium for whom there was an assessment for the presence or absence of at least one of the following potential causes and their association with delirium: medication effects, central nervous system disease, infection, or metabolic processes.

RAND Corporation

  • Measure Summary
  • NQMC:006132
  • 2010 Apr

Cancer - depression and psychosocial distress: percentage of patients treated for depression for whom a response to therapy was documented within 6 weeks.

RAND Corporation

  • Measure Summary
  • NQMC:006147
  • 2010 Apr

Cancer - dyspnea: percentage of patients who reported new or worsening dyspnea for whom there was documentation of cause or of investigation of at least one of the following: hypoxia, anemia, bronchospasm or chronic obstructive pulmonary disease, pleural effusion, tumor obstruction of bronchi or the trachea, pneumonia, or pulmonary embolism.

RAND Corporation

  • Measure Summary
  • NQMC:006135
  • 2010 Apr

Cancer - nausea and vomiting: percentage of patients undergoing chemotherapy treatment with a high acute emetic risk for whom a 3-drug regimen including single doses of a 5-HT3 receptor antagonist, dexamethasone, and selective neurokinin-1 receptor blocker was given immediately prior to chemotherapy.

RAND Corporation

  • Measure Summary
  • NQMC:006138
  • 2010 Apr

Cancer - nausea and vomiting: percentage of inpatients with nausea or vomiting who were offered a change in therapy within 24 hours of the initial report of nausea or vomiting.

RAND Corporation

  • Measure Summary
  • NQMC:006128
  • 2010 Apr

Cancer - pain: percentage of patients with new neurologic symptoms or findings on a physical examination consistent with a spinal cord compression for whom a whole-spine magnetic resonance imaging (MRI) scan or myelography was performed as soon as possible, but within 24 hours OR there was documentation of why an MRI scan was not appropriate.

RAND Corporation

  • Measure Summary
  • NQMC:006122
  • 2010 Apr

Cancer - pain: percentage of patients admitted to the hospital who were screened for the presence or absence of pain.

RAND Corporation

  • Measure Summary
  • NQMC:006150
  • 2010 Apr

Cancer - dyspnea: percentage of patients in the hospital treated for dyspnea who had an assessment within 24 hours that the treatment was effective in relieving dyspnea or that a change in treatment for dyspnea was made.

RAND Corporation

  • Measure Summary
  • NQMC:006156
  • 2010 Apr

Cancer - skin rash: percentage of patients treated with agents that block epidermal growth factor receptors (EGFRs) for whom the presence and severity of skin rash was evaluated within one month after starting the treatments and at each visit.

RAND Corporation

  • Measure Summary
  • NQMC:006153
  • 2010 Apr

Cancer - diarrhea: percentage of patients undergoing chemotherapy who have diarrhea for whom all of the following were assessed: history of onset and duration, number of stools and stool composition, and at least one of the associated symptoms (fever, dizziness, abdominal pain/cramping, nausea/vomiting, decreased performance status, sepsis, fever, bleeding, or dehydration), in order to classify the diarrhea as complicated or uncomplicated.

RAND Corporation

  • Measure Summary
  • NQMC:006142
  • 2010 Apr

Cancer - fatigue/anemia: percentage of patients found to have anemia with a hemoglobin less than 10 g/dl for whom the presence and severity of anemia-related symptoms (e.g., fatigue, dyspnea, and lightheadedness) were evaluated.

RAND Corporation

  • Measure Summary
  • NQMC:006159
  • 2010 Apr

Cancer - information and care planning: percentage of patients with advanced cancer who are admitted to the ICU and survive 48 hours for whom the patient's preferences for care or an attempt to identify them was documented in the medical record within 48 hours of ICU admission.

RAND Corporation

  • Measure Summary
  • NQMC:006136
  • 2010 Apr

Cancer - nausea and vomiting: percentage of patients undergoing chemotherapy treatment with a moderate acute emetic risk for whom a 2-drug regimen including a 5-HT3 receptor antagonist and dexamethasone were given immediately prior to chemotherapy.

RAND Corporation

  • Measure Summary
  • NQMC:006151
  • 2010 Apr

Cancer - dyspnea: percentage of patients with dyspnea and a malignant pleural effusion who were offered thoracentesis within one month of the initial diagnosis of the effusion, or other treatment (e.g., diuresis) that resulted in a reduction in the effusion or symptomatic dyspnea.

RAND Corporation

  • Measure Summary
  • NQMC:006123
  • 2010 Apr

Cancer - pain: percentage of patients with cancer pain started on a long-acting opioid formulation for whom a short-acting opioid formulation for breakthrough pain was also provided.

RAND Corporation

  • Measure Summary
  • NQMC:006126
  • 2010 Apr

Cancer - pain: percentage of patients with advanced cancer who received radiation treatment for painful bone metastases for whom single-fraction radiation was offered OR there was documentation of a contraindication to single-fraction treatment.

RAND Corporation